D-0100-2024 Class I Terminated
FDA drug recall D-0100-2024 was initiated by Pfizer Inc. on Oct 2, 2023 and is designated Class I. Reason for recall: Presence of Particulate Matter: identified as glass. The recall status is terminated (terminated Feb 14, 2025). Affected quantity: 24,900 vials.
Recall details
- Product Type
- Drugs
- Report Date
- Nov 15, 2023
- Initiation Date
- Oct 2, 2023
- Termination Date
- Feb 14, 2025
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 24,900 vials
Product description
4.2% Sodium Bicarbonate Injection, USP 5 mEq/10 mL (0.5mEq/mL), Glass ABBOJECT Unit of Use Syringe, packaged as 1 vial and injector per carton, Rx only, Hospira Inc., Lake Forest, IL 60045, NDC 0409-5534-24
Reason for recall
Presence of Particulate Matter: identified as glass.
Distribution pattern
Nationwide in the US and Puerto Rico. The products were not distributed to government accounts or foreign consignees.
Code information
Lot#: GJ5007, Exp. 8/1/2024
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0100-2024
- openFDA file date
- Nov 19, 2026
- Loaded by RegDataLab
- Nov 20, 2026
Need the full FDA record for Pfizer Inc.? Ask Claude or ChatGPT with the RegDataLab connector and get every site's inspections, Form 483s, warning letters, recalls and import alerts, each with a link to the FDA source. The API key is free: no card.